| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A Mancini, P Zuppi, C Fiumara, D Valle, G Conte, M L Fabrizi, L Sammartano, C Anile, G Maira, L De Marini. GH response to oral and intravenous glucose load in acromegalic patients. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 27. issue 7. 1995-12-12. PMID:7590615. |
the lack of inhibition of growth hormone (gh) levels after glucose load is considered a marker of inappropriate gh secretion in acromegaly. |
1995-12-12 |
2023-08-12 |
Not clear |
| D J O'Halloran, S M Shale. Acromegaly: unravelling a complex disease. Growth regulation. vol 5. issue 3. 1995-12-07. PMID:7580862. |
this gh value correlates well with that required to normalize the serum igf-1 concentration, a gh-dependent peptide which can be used to monitor the disease activity in acromegaly. |
1995-12-07 |
2023-08-12 |
Not clear |
| M Arosio, S Macchelli, C M Rossi, G Casati, O Biella, G Fagli. Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group. European journal of endocrinology. vol 133. issue 4. 1995-11-30. PMID:7581966. |
treatment of acromegaly is effective in reversing the reduced life-span of patients only when serum growth hormone (gh) concentrations are lowered to less than 2.5 micrograms/l. |
1995-11-30 |
2023-08-12 |
Not clear |
| S Ezzat, D A Redelmeier, M Gnehm, A G Harri. A prospective multicenter octreotide dose response study in the treatment of acromegaly. Journal of endocrinological investigation. vol 18. issue 5. 1995-11-30. PMID:7594225. |
this report describes the effects of escalating doses of octreotide on the growth hormone (gh) profiles, insulin-like growth factor-1 (igf-1), prolactin (prl), and adverse effects in 99 patients with acromegaly. |
1995-11-30 |
2023-08-12 |
human |
| R Rapaport, I N Sills, L Green, P Barrett, J Labus, K A Skuza, A Chartoff, L Goode, M Stene, B H Peterse. Detection of human growth hormone receptors on IM-9 cells and peripheral blood mononuclear cell subsets by flow cytometry: correlation with growth hormone-binding protein levels. The Journal of clinical endocrinology and metabolism. vol 80. issue 9. 1995-10-17. PMID:7673403. |
using two-color flow cytometry, we identified ghr on circulating b lymphocytes in subjects with gh deficiency (n = 9), precocious puberty (n = 6), and turner syndrome (n = 5) and in seven subjects with miscellaneous disorders, including familial short stature, bone dysplasia, crohn disease, congenital adrenal hyperplasia, and acromegaly. |
1995-10-17 |
2023-08-12 |
human |
| W W de Herder, P Uitterlinden, A J van der Lely, L J Hofland, S W Lambert. Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly. European journal of endocrinology. vol 133. issue 2. 1995-10-02. PMID:7544670. |
twenty-three patients with active acromegaly underwent serum sampling for growth hormone (gh), insulin and insulin-like growth factor binding protein 1 (igfbp-1) after placebo or single doses of octreotide or bromocriptine. |
1995-10-02 |
2023-08-12 |
Not clear |
| W W de Herder, P Uitterlinden, A J van der Lely, L J Hofland, S W Lambert. Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly. European journal of endocrinology. vol 133. issue 2. 1995-10-02. PMID:7544670. |
bromocriptine caused a non-significant increase in integrated 24-h serum igfbp-1 levels, which argues against a direct regulatory effect of gh on igfbp-1 production in acromegaly. |
1995-10-02 |
2023-08-12 |
Not clear |
| C Campino, J Szecowka, J M Lopez, M Seron-Ferr. Bioactive GH-like immunoglobulins G in active acromegaly: response to long-term treatment with bromocriptine. Clinical endocrinology. vol 43. issue 1. 1995-09-19. PMID:7641402. |
in acromegaly, certain forms of circulating immunoreactive hgh are not true gh but iggs which possess gh biological activity (bioactive gh-like iggs). |
1995-09-19 |
2023-08-12 |
Not clear |
| N S Levitt, B D Ratanjee, M J Abrahamso. Do "so-called" normal growth hormone concentrations (2-5 micrograms/l) indicate cure in acromegaly? Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 27. issue 4. 1995-06-22. PMID:7750902. |
22 patients with acromegaly, 22 post surgery, 19 post radiotherapy had gh concentrations estimated during: (i) an oral glucose tolerance test (ogtt), (ii) a standard trh test and (iii) 20 minute sampling for 8 hours. |
1995-06-22 |
2023-08-12 |
human |
| P J Ho, N Gesundheit, W L Wong, S H Huang, R D Friberg, A L Barka. Dynamic changes of growth hormone-binding protein concentrations in normal men and patients with acromegaly: effects of short-term fasting. Metabolism: clinical and experimental. vol 44. issue 5. 1995-06-21. PMID:7752917. |
plasma concentrations of growth hormone (gh) and gh-binding protein (ghbp) were measured at hourly intervals in five healthy men and five patients with acromegaly during the fed state and after a 5-day fast. |
1995-06-21 |
2023-08-12 |
Not clear |
| A S Bates, A J Evans, P Jones, R N Clayto. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clinical endocrinology. vol 42. issue 4. 1995-06-19. PMID:7750196. |
assessment of gh status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. |
1995-06-19 |
2023-08-12 |
human |
| H Watanobe, T Tamur. Clinical significance of the growth hormone response to vasoactive intestinal peptide and gonadotropin-releasing hormone in acromegaly. Neuropeptides. vol 28. issue 2. 1995-06-14. PMID:7746355. |
in this study, we examined whether the loading of vasoactive intestinal peptide (vip) and gnrh, another hypothalamic hormone capable of stimulating gh secretion in acromegaly, have a pathophysiological significance as trh, ghrh, and br tests. |
1995-06-14 |
2023-08-12 |
Not clear |
| H Watanobe, T Tamur. Clinical significance of the growth hormone response to vasoactive intestinal peptide and gonadotropin-releasing hormone in acromegaly. Neuropeptides. vol 28. issue 2. 1995-06-14. PMID:7746355. |
in 52 patients with active acromegaly, we performed iv bolus injections of trh (500 micrograms), ghrh (100 micrograms), vip (100 micrograms), and gnrh (100 micrograms), and a peroral administration of br (2.5 mg), in order to compare the gh responses to these loads. |
1995-06-14 |
2023-08-12 |
Not clear |
| H Watanobe, T Tamur. Clinical significance of the growth hormone response to vasoactive intestinal peptide and gonadotropin-releasing hormone in acromegaly. Neuropeptides. vol 28. issue 2. 1995-06-14. PMID:7746355. |
from these results, we hypothesize that the positive gh responsiveness to vip and gnrh, like that to ghrh, may be a feature of the somatotroph-like pituitary adenoma causing acromegaly. |
1995-06-14 |
2023-08-12 |
Not clear |
| H Watanobe, T Tamur. Clinical significance of the growth hormone response to vasoactive intestinal peptide and gonadotropin-releasing hormone in acromegaly. Neuropeptides. vol 28. issue 2. 1995-06-14. PMID:7746355. |
the present results appear to be of some help in understanding the basis of the great variabilities in the gh responses to various dynamic testings in acromegaly. |
1995-06-14 |
2023-08-12 |
Not clear |
| A Giustina, E Bresciani, A R Bussi, A Bollati, C Bonfanti, G Bugari, L Chiesa, G Giustin. Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly. The Journal of clinical endocrinology and metabolism. vol 80. issue 4. 1995-05-12. PMID:7536207. |
the aim of our study was to ascertain the incidence, entity and mechanism of the paradoxical gh inhibitory effect of galanin in acromegaly also looking at possible correlations between the gh responses to galanin and the main clinical and biochemical features of the patients. |
1995-05-12 |
2023-08-12 |
human |
| A Giustina, E Bresciani, A R Bussi, A Bollati, C Bonfanti, G Bugari, L Chiesa, G Giustin. Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly. The Journal of clinical endocrinology and metabolism. vol 80. issue 4. 1995-05-12. PMID:7536207. |
finally, the effects of either successful or unsuccessful neurosurgical intervention on the gh inhibitory effect of galanin in acromegaly were investigated. |
1995-05-12 |
2023-08-12 |
human |
| A Giustina, E Bresciani, A R Bussi, A Bollati, C Bonfanti, G Bugari, L Chiesa, G Giustin. Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly. The Journal of clinical endocrinology and metabolism. vol 80. issue 4. 1995-05-12. PMID:7536207. |
in conclusion, we demonstrated that the large majority of numerous patients with active acromegaly show a decrease in serum gh levels after galanin administration. |
1995-05-12 |
2023-08-12 |
human |
| P P Feuillan, J Jones, J L Ros. Growth hormone hypersecretion in a girl with McCune-Albright syndrome: comparison with controls and response to a dose of long-acting somatostatin analog. The Journal of clinical endocrinology and metabolism. vol 80. issue 4. 1995-05-12. PMID:7714111. |
gh every 20 min for 24 h, insulin-like growth factor i (igf-i), igf-binding protein 3, and estradiol (e2) were measured in a 7.3-yr-old girl with precocious puberty due to mccune-albright syndrome (mas) who developed stigmata of early acromegaly and in 9 other mas patients who had no signs of acromegaly. |
1995-05-12 |
2023-08-12 |
Not clear |
| Y Greenman, D Prager, S Melme. The IGF-I receptor sub-membrane domain is intact in GH-secreting pituitary tumours. Clinical endocrinology. vol 42. issue 2. 1995-05-08. PMID:7704960. |
clinical acromegaly is characterized by dysregulation of somatotroph gh secretion in the presence of high circulating serum igf-i levels. |
1995-05-08 |
2023-08-12 |
Not clear |